ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/pancreas/advanced-metastatic/first-line-including-maintenance
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Pancreas - Advanced/metastatic / First line including maintenance
5
trial(s) found.
NCT07522073
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously
Untreated
, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (
DAWN-303
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Pancreatic adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
QLD
4032 - Chermside - Icon Cancer Care Chermside
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07491445
Advanced
Phase 3
Recruiting
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a
First-Line
Treatment for Patients With Metastatic Pancreatic Adenocarcinoma (
RASolute-303
)
antimetabolite
pan-RAS inhibitor,tricomplex inhibitor
taxane
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT07490301
Advanced
Phase 2 / Phase 3
Recruiting
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With
First-Line
Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288 (
M25-288
)
anti-cMET antibody-drug conjugate
Pancreatic adenocarcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06989437
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background
First-Line
Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma (
C3651021
)
anti-GDF15 monoclonal antibody
placebo
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT05254171
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously
Untreated
for Metastatic Pancreatic Ductal Adenocarcinoma (
ASPIRE
)
antimetabolite
placebo
polyamine analogue
taxane
Pancreatic adenocarcinoma
Pancreatic cancer
NSW
2485 - Tweed Heads - The Tweed Hospital (WITHDRAWN)
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Glandore - Ashford Cancer Centre
WA
6150 - Murdoch - St John of God Murdoch Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Recruitment Country and State
VIC (5)
NSW (3)
SA (3)
ACT (2)
QLD (2)
WA (2)
NZ (1)
TAS (1)
Phase
Phase 2 / Phase 3 (3)
Phase 3 (2)
Trial Type
Advanced (5)
Cancer Therapy Class
KRAS
40%
MET
20%
GDF15
20%
Facility
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2605 - Garran - The Canberra Hospital (2)
2109 - North Ryde - Macquarie University Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
2217 - Kogarah - St George Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3002 - East Melbourne - Epworth Freemasons (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2485 - Tweed Heads - The Tweed Hospital (1)
5037 - Glandore - Ashford Cancer Centre (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
Cancer Type
Cancer
Exocrine pancreatic cancer
Gastrointestinal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Solid tumour
Upper gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy